Statins for Primary Prevention of Cardiovascular Disease in Germany: Benefits and Costs

Alexander Dressel,Felix Fath,Bernhard Kraemer,Gerald Klose,Winfried Maerz

DOI: https://doi.org/10.1101/2024.10.17.24315649

2024-10-17

Abstract:Background The reduction of LDL cholesterol lowers the risk of coronary and cerebrovascular events in individuals without manifest cardiovascular diseases. In Germany, statins may only be prescribed at the expense of statutory health insurance for patients with atherosclerosis-related diseases or those at high cardiovascular risk (over 20 percent event probability within the next 10 years, calculated using one of the "available risk calculators"). However, international guidelines recommend lower risk thresholds for the use of statins. Methods The health and economic impacts of different risk thresholds for statin use in primary prevention within the German population are estimated for thresholds of 7.5, 10, and 15 percent over 10 years, based on the US Pooled Cohort Equation (PCE) which has been validated for Germany, using Markov models. Findings Cost-effectiveness increases with a rising risk threshold, while individual benefit decreases with age at the start of treatment. The use of statins at a risk of 7.5 percent or more is cost-effective at any age (cost per QALY between 410 and 2,100 euros). In none of the examined scenarios does the proportion of the population qualifying for statin therapy exceed 25 percent. Interpretation Lowering the threshold for statin therapy based on age to a risk of 7.5 percent, estimated with the US PCE, aligns statin prescription with international standards. There is no urgent rationale for applying age-stratified risk thresholds using the SCORE2 proposed for Europe, which tends to underestimate actual risks.

Health Economics

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the cost - effectiveness analysis of using statins for primary prevention of cardiovascular diseases in Germany, especially the application situation under different risk thresholds. Specifically, the study aims to evaluate the health and economic impacts of using statins for primary prevention under different risk thresholds (10 - year cardiovascular event risks of 7.5%, 10% and 15%) determined by the Pooled Cohort Equation (PCE) in the German population.

### Research Background
- **Reducing LDL Cholesterol**: Reducing low - density lipoprotein cholesterol (LDL - C) can reduce the risk of coronary and cerebrovascular events, even in people without obvious cardiovascular diseases.
- **Current Regulations in Germany**: In Germany, statins can only be reimbursed by the statutory health insurance when the patient has atherosclerotic - related diseases or high cardiovascular risk (the probability of events within 10 years exceeds 20%).
- **Recommendations in International Guidelines**: International guidelines recommend using lower risk thresholds to initiate statin treatment.

### Research Methods
- **Model Construction**: Use the Markov model to simulate the incidence, cost and benefit of cardiovascular events in individuals starting treatment at different ages (25, 40, 50, 60 and 70 years) under different risk thresholds (7.5%, 10% and 15% of 10 - year risk).
- **Data Sources**: Use the mortality data of the general German population from 2017 to 2019, excluding the special effects during the COVID - 19 pandemic.
- **Event Rate Calculation**: The incidences of non - fatal coronary heart disease and cerebrovascular events are calculated based on the proportions of fatal events (2.89 and 3.31 respectively).

### Main Findings
- **Cost - effectiveness**: As the risk threshold increases, the cost - effectiveness increases, but the individual benefit decreases as the age of starting treatment increases.
- **Treatment Effect**: At the risk threshold of 7.5%, using statins is cost - effective at any age (the cost per QALY is between €410 and €2,100). In all the scenarios examined, the proportion of the population eligible for statin treatment does not exceed 25%.
- **Budget Impact**: From the payer's perspective, the cost depends on the selected risk threshold and the time of starting treatment. The cost ranges from €0.49 million to €1.93 million.

### Explanation and Discussion
- **Reducing the Risk Threshold**: Reducing the risk threshold to 7.5% (calculated using PCE) can make the prescription of statins in line with international standards. The SCORE2 risk calculator used in Europe tends to underestimate the actual risk, so there is no urgent reason to use age - stratified risk thresholds.
- **Age Factor**: As age increases, competing risks increase, which leads to a decrease in the absolute benefit of treatment.
- **Cost - effectiveness**: Even at a lower global risk threshold (less than 20% within 10 years), statin treatment is still effective and cost - effective.

### Conclusion
This study analyzed the effects and cost - effectiveness of using statins for primary prevention of cardiovascular diseases under different risk thresholds through modeling. The results show that reducing the risk threshold to 7.5% is cost - effective and in line with international standards. However, the age of starting treatment has a significant impact on individual benefits and needs to be comprehensively considered in clinical practice.